Mundipharma International Limited

Cidara Therapeutics’ business outlook improved substantially on June 23 after releasing pre-market Phase IIb data for its non-vaccine seasonal influenza prevention agent showing better prophylaxis cap

A lot of biopharmaceutical companies have changed their strategies during the past year or two with investors less receptive to stock offerings in 2022 and 2023 than they were in the two prior years,

Cidara Therapeutics, Inc. took a series of steps 24 April that completely reinvent the company, essentially forming a new company with a new focus, Cidara CEO Jeffrey Stein said in an interview. Abou

In 2023, the European Commission approved 36 medicines containing a new active substance, the lowest number since 2019 when just 28 NAS-containing drugs gained an EU-wide marketing authorization. Amon